A One-Dose Wonder for Influenza Post-Exposure Prophylaxis

A One-Dose Wonder for Influenza Post-Exposure Prophylaxis

Influenza season is upon us. This course discusses baloxavir marboxil as a post-exposure influenza prophylaxis and treatment. Learn which patients are candidates and how it compares with other available antiviral medications.

Upon successful completion of this application-based course, pharmacists and pharmacy students should be able to:
1. Describe the mechanism of action and clinical pearls of baloxavir marboxil.
2. Discuss the results of the clinical trial that support baloxavir marboxil for influenza post-exposure prophylaxis.
3. Develop a conclusion for the clinical appropriateness of care based on a clinical trial
4. Identify patients who are candidates to receive baloxavir marboxil for influenza post-exposure prophylaxis.
5. Compare and contrast baloxavir marboxil with other available influenza antiviral medications.

Letitia Warunek
Assistant Professor
Wilkes University, School of Pharmacy

Letitia Warunek does not report any actual or potential conflicts of interest in relation to this continuing pharmacy education course. 

CEimpact is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. To obtain 1 contact hour of continuing pharmacy education credit (0.1 CEU), participants must read:

Ikematsu H, Hayden F, Kawaguchi K, et al. Baloxavir Marboxil for Prophylaxis against Influenza in Household Contracts. N Engl J Med 2020;383:309-20. DOI: 10.1056/NEJMoa1915341. Available at: https://www.nejm.org/doi/full/10.1056/NEJMoa1915341

The article this month is from The New England Journal of Medicine and may be behind a paywall. We encourage preceptors to take advantage of journal access through university affiliation. Additionally, a free account to NEJM.org provides access to 2 subscriber-only articles per month, if access through a university is not possible. If you have any questions, please contact us at team@ceimpact.com.  

*CEimpact provides you with two (2) opportunities to complete the exam. If there are two failed attempts, the participant will not receive CPE credit.

This course is included in our Pharmacist Subscription Service. To get more courses like this sent to you every month, sign-up for a CE Subscription Service!

Fee includes course, course materials, and CPE credit submission to CPE Monitor.
Course is non-refundable.
Initial Release Date: April 14, 2021
Planned Expiration Date: April 14, 2024

Universal Activity Number (UAN): 0107-0000-21-041-H01-P
Application-based CPE Activity

CEImpact is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Obtain CPE credit by completing the course, followed by the exam and evaluation (if applicable). Once successfully completed, your course will appear in your Completed Courses tab. Access your CPE statement of credit at www.MyCPEMonitor.net.

¹CEImpact provides you with two (2) opportunities to complete the exam. The learner will not receive CPE credit after two failed attempts.

Additional information

Duration

1h 0m

Topic Designator

Disease State/Drug Therapy

ACPE

Yes

ACPE Topic

01 Drug Therapy

Role

Pharmacist

Media-Type

On-Demand

Release Date

4/15/21

CEUs

0.1

Rating

4

ACPE Number

0107-0000-21-041-H01-P

This course is in our subscription.

0